BRUXISM TREATMENT MARKET ANALYSIS

Bruxism can be described as involuntary or excessive bruxism. In bruxism, the chewing surfaces of the upper and lower teeth come into contact with each other. Bruxism can occur while awake, called waking or daytime bruxism, and it can occur during sleep, known as sleep or nocturnal bruxism.  Bruxism can be divided into primary and secondary bruxism.

Global bruxism treatment market is estimated to be valued at US$ 1,143.1 million in 2022 and is expected to exhibit a CAGR of 6.6% during the forecast period (2022-2030).

Analysts’ Views on Global Bruxism Treatment Market:

The bruxism treatment market's growth can be hindered by the presence of alternative treatment methods for bruxism, such as exercise, yoga, and meditation. Similarly, in April 2021, according to the website of TOTALLY ORTHODONTICS, an orthodontist, increasing intake of vitamin C may help reduce the clenching and grinding of teeth, particularly when prioritized along with participation in cognitive behavioral therapy or stress management techniques. Moreover, vitamin C contributes to increase ability to respond to stress and to regulate patient’s moods, whereas B-vitamin deficiency can trigger symptoms associated with bruxism, including panic attacks, stress, and depression. Vitamin B5 has been associated with a balanced mood that is helpful in addressing bruxism.

Figure 1.Global Bruxism Treatment Market Share (%), by Product Type, 2022

To learn more about this report, request a free sample copy

 Global Bruxism Treatment Market- Driver

Product approval for the bruxism treatment

Major companies operating in the global bruxism treatment market are focused on organic growth strategies such as product approval, which is expected to drive growth of the global bruxism treatment market over the forecast period. For instance, in November 2021, the U.S. Food and Drug Administration (FDA) had given SprintRay Inc., a company involved in digital dentistry and 3D printing solutions, approval to market its NightGuard Flex 3D printing resin as a Class II medical device in the U.S. NightGuard Flex resin is used in the treatment of bruxism.

The Increasing Prevalence of Bruxism

The increasing prevalence of bruxism, stress, and anxiety is expected to drive the market growth over the forecast period. For instance, on February 3, 2022, according to the report published by Up to Date, an evidence-based clinical resource company, bruxism affects approximately 15% to 40% of children and 8% to 10% of adults globally. According to the same source, in children, bruxism may occur as early as the appearance of the first teeth; the prevalence then increases to approximately 30% by the age of six years. In adults, the prevalence rates peak at about 12% in young adults and fall to 2% to 4% by age 60 years.

Figure 2. Global Bruxism Treatment Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

Global Bruxism Treatment Market- Regional Analysis

Among all regions North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 37.8% market share and increasing inorganic strategies such as acquisition by key players in the region. For instance, on January 10, 2022, National Dentex Labs, a dental laboratory network company in North America, announced the acquisition of Biotech Dental Prosthetics located in Palm Beach Gardens, Florida. Terms of the acquisition has not been disclosed.

The Europe region is expected to second largest region over the forecast period. Due to increasing research and development activity by key players in the region. For instance, on May 25, 2022, Centre Hospitalier Universitaire Dijon, France, initiated a clinical trial study on Efficacy of Botulinum Toxin A in the treatment of Bruxism-related Symptomatology (Botox). The clinical trial study is currently in phase 3 and actively recruiting volunteers.

Global Bruxism Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to World Health Organization (WHO) as of October 10, 2022, 44,614,437 people are affected worldwide.

The COVID-19 pandemic caused uncertainty, isolation, and disruptions in routine, thus, this resulted in increase in physical and mental health problems and dentists noticed an increase in teeth grinding and jaw clenching, known as bruxism. For instance, According to an article published in National Center for Biotechnology Information in June 2022, the relative search volume of bruxism, teeth grinding, and teeth clenching was not significantly different between 2020 and 2016–2019 globally or in the U.S. in the March 15, 2020 to May 9, 2020 period. Only the search for teeth grinding showed an increase globally. In the May 10, 2020 to October 17, 2020 period, the relative search volume of bruxism, teeth grinding, and teeth clenching all was significantly higher in 2020 compared to 2016–2019 both globally and in the U.S.

Global Bruxism Treatment Market Segmentation:

The global betamethasone acetate market report is segmented into product type, patient type and end user

Based on Product Type, the market is segmented into Mouth Guards and NTI-tss, and Splints. Out of which, NTI-tss and Splints segment is expected to dominate the bruxism treatment market during the forecast period and this is attributed due to increase in the usage of NTI-tss and Splints for treatment of bruxism.

Based on Patient Type, the market is segmented into an Adults and Pediatric. Out of which, Adult segment is expected to dominate the market over the forecast period and this is attributed due to increase in the pipeline studies regarding bruxism treatment for adults.

Based on End User, the bruxism treatment market is segmented into Hospitals, Dental Clinics, Homecare Settings, and Others. Dental Clinics segment is expected to dominate the market over the forecast period and this is attributed to the availability of advanced products for treatment of bruxism in dental clinics.

Among all segmentation, patient type segment has highest potential due to high demand of bruxism treatment products in adult population. For instance, on February 15, 2022, according to the report published by Anxiety and Depression Association of America, approximately 264 million adults around the globe had anxiety in between 2018-2019.

Global Bruxism Treatment Market Cross Sectional Analysis:

In product type segment, NTI-tss and Splints held as a dominant segment in North America region due to the increasing product approval. For instance, according to an article published in Journal of Dentistry and Oral Sciences in May 2022, occlusal splint is used to prevent damage from symptoms of bruxism. An occlusal splint is recommended as the first line of protection against noise bruxism and tooth wear in patients suffering from sleep bruxism. The use of an occlusal splint improves patient comfort by lowering muscular activity. It indicates that using an occlusal splint lessens orofacial pain, masticatory muscle tension, and teeth grinding.

In Patient type segment, adult segment is dominant in Asia Pacific region due to increasing number of adult population. For instance, in June 2022, according to data provided by the U.S. Census Bureau, as of 2020, Asia Pacific had over 4.5 billion people (including China and India, each with over 1 billion people), accounting for more than half of the world's population.

Global Bruxism Treatment Market: Key Developments

On October 7, 2022, Desktop Health, a healthcare business within Desktop Metal, Inc., a company focused on developing 3D printing solutions for personalized medicine, announced that it had received the U.S. Food and Drug Administration (FDA) 510(k) clearance of SmileGuard resin, a light, biocompatible material for the fabrication of strong & flexible bite splints and other orthodontic and dental appliances.

On November 17, 2022, RespireRx Pharmaceuticals Inc., a pharmaceutical company, announced that on November 14, 2022, the company entered into a letter of intent (LOI) with an Australia headquartered, bespoke clinical research organization focused on cannabinoid and psychedelic clinical research. Under the contract, the CRO (clinical research organization) is expected to provide full service CRO services, including regulatory, compliance, and GMP (good manufacturing practices) manufacturing services in addition to human pharmacokinetic and pivotal human efficacy and safety studies of dronabinol for the treatment of obstructive sleep apnea.

On June 23, 2022, Yenepoya (Deemed to be University), Karnataka, India and DentCare Dental Lab Pvt. Ltd, Muvattupuzha, in Kerala, India signed a memorandum of understanding (MoU). Yenepoya is taking a major step towards providing an opportunity to aspiring candidates intending to make a career in dental technology.

Global Bruxism Treatment Market: Restraint

Drawbacks associated with bruxism treatment

The major factors that can hamper growth of the global bruxism treatment market over the forecast period include the drawbacks associated with the devices used in the treatment of Bruxism. For instance, according to the website of Dental Care, a dental service providing company, custom made night guards (mouth guard) are expensive, and they are not always covered under the medical insurance policies. Moreover, if the patient has jaw pain resulting from bruxism, the patient may find it very painful to open their mouth wide, making large dental impressions more painful. The key players in the market should focused on developing medical devices having less drawbacks to increase the device potentials

Global Bruxism Treatment Market: Key Players

Major players operating in the global bruxism treatment market include Randmark Dental Products, LLC., S4S (UK) Limited, DentCare Dental Lab Pvt.Ltd., Glidewell, Burbank Dental Lab, Brux Night Guard, CUSTMBITE, DDS Lab, Watersedge Dental Laboratory Inc., Orofacial Therapeutics, LP., PFL Healthcare Limited, Keystone Industries, Artistic Dental Laboratories, Inc., Iverson Dental Laboratories, National Dentex Labs (NDX), BonaDent Dental Laboratories, Procter & Gamble